免疫调节药物治疗多发性骨髓瘤的临床应用进展  

The progress of clinical application of immunomodulatory drugs in the treatment of multiple myeloma

作　　者：范传莲 李海亮 FAN Chuan-lian;LI Hai-liang(The First Clinical Medical School,Gannan Medical University;Department of Hematology,The First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi 341000)

机构地区：[1]赣南医科大学第一临床医学院 [2]赣南医科大学第一附属医院血液内科,江西赣州341000

出　　处：《赣南医学院学报》2024年第4期428-434,共7页JOURNAL OF GANNAN MEDICAL UNIVERSITY

摘　　要：多发性骨髓瘤是一种恶性浆细胞克隆性增殖所致的疾病,是血液系统第二常见恶性肿瘤。主要临床表现为血钙增高、肾功能损害、贫血、骨损害以及继发淀粉样变性等。尽管目前应用于治疗多发性骨髓瘤的方法有多种,但患者仍无法治愈,大多数患者最终都会复发。而免疫调节药物的引入使多发性骨髓瘤患者生存结局得到显著改善,是多发性骨髓瘤患者治疗的基石,贯穿于治疗的每一个阶段。本文主要讨论免疫调节药物作用机制及总结目前免疫调节药物在多发性骨髓瘤临床治疗中的应用。Multiple myeloma,the second most common malignancy of the blood system,is a malignant clonal proliferative disease of plasma cells.The main clinical manifestations are increased blood calcium,renal impairment,anemia,bone damage,and secondary amyloidosis.Although there are many clinical approaches available for multiple myeloma,there is no cure for the disease,and most patients eventually relapse.The introduction of immunomodulatory drugs has significantly improved the survival outcome of patients with multiple myeloma and is a cornerstone of the treatment of multiple myeloma patients throughout every stage of treatment.This article discusses the mechanism of action of immunomodulatory drugs and summarizes the current application of immunomodulatory drugs in the clinical treatment of multiple myeloma.

关 键 词：多发性骨髓瘤 免疫调节药物 临床应用 

分 类 号：R551.3[医药卫生—血液循环系统疾病]